N8 Medical, LLC news
N8 Medical, LLC (N8 Medical) today announced its first-in-human clinical trials of its flagship CeraShield™ endotracheal tube (CeraShield™ ETT) for intensive care unit patients expected to require mechanical ventilation for more than 48 hours. N8 Medical is encouraged by preliminary study data and believes that the CeraShield™ ETT will demonstrate safety and a significant reduction in bacterial and fungal fouling of the tube. Fouling of endotracheal tubes is associated with
N8 Medical, LLC, a privately held biotechnology company, today announced that its CeraShield™ coated endotracheal tubes significantly reduced the growth of COVID-19 virus in recent testing. The testing shows statistically significant reduction in the growth of the COVID-19 virus on the tube surface in 60 minutes. Ordinary uncoated endotracheal tubes either allowed increased virus growth or had no inhibitory effect.
“Recent COVID-19 research has shown tha
N8 Medical, LLC (N8 Medical) today announced that Health Canada has granted Dr. John Muscedere of Kingston General Hospital’s emergency request to begin using the N8 Medical CeraShield™ Endotracheal Tubes in mechanically-ventilated COVID-19 patients.
N8 Medical’s CeraShield™ Endotracheal Tube has a patented anti-fouling coating that is designed to prevent deadly bacterial infections that frequently occur in ventilated patients with respiratory viral infections.
N8 Medical, LLC (N8 Medical) today announced it has been selected as the winner of a North American New Product Innovation Award by Frost & Sullivan, a leader in global research and consulting solutions.
N8 Medical is developing disruptive medical devices that prevent hospital-acquired infections and their expensive and potentially fatal consequences. N8 Medical earned the award for its proprietary platform CeraShield™ technology that provides significant surface antifouling
N8 Medical, a clinical-stage biopharmaceutical company focused on developing novel combination medical devices and antifungal and anti-bacterial therapeutics for the prevention and treatment of serious and life-threatening infections, announced today that it appointed David S. Perlin, Ph.D. to its Scientific Advisory Board (SAB).
Dr. Perlin is an internationally recognized expert and research scientist in infectious diseases